Any experience with Pioglitazone (Actos)? Apparently it's great for insulin resistance

CronosTempi · 2025-08-11T00:21:01.047Z

Empagliflozin and pioglitazone do not appear to have adverse DDI (drug drug interactions), at least short term. Why is this important - because this was in healthy people.

Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers

PubMed

Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in...

These results indicate that pioglitazone and empagliflozin can be coadministered without dose adjustments. EudraCT identifiers: 2008-006087-11 (study 1) and 2009-018089-36 (study 2).

Regarding bladder cancer and lack of treatment options - progress is being made:

New treatment eliminates bladder cancer in 82% of patients

New treatment eliminates bladder cancer in 82% of patients

LOS ANGELES — A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously resisted treatment. In the...

CV health and pioglitazone:

Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials

PubMed

Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of...

The use of pioglitazone does not appear to be harmful in terms of cardiovascular events and all-cause deaths.

This is an interesting paper on genetic variability affecting pioglitazone:

Current clinical evidence on pioglitazone pharmacogenomics

PubMed Central (PMC)

Current clinical evidence on pioglitazone pharmacogenomics

Pioglitazone is the most widely used thiazolidinedione and acts as an insulin-sensitizer through activation of the Peroxisome Proliferator-Activated Receptor-γ (PPARγ). Pioglitazone is approved for use in the management of type 2 diabetes mellitus...